95957 20230914083240.0 doi 10.3332/ECANCER.2019.998 sideral 116394 ART-2020-116394 eng Walker, J. Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: Benefits and risks of antithrombotic therapy for cardiovascular disease prevention 2020 Access copy available to the general public Unrestricted At the 2019 International Aspirin Foundation Scientific Conference ‘Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit. info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 0.707 2020 Oncology 2020 Q3 Cancer Research 2020 Q3 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Cattaneo, M. Badimon, L. Agnelli, G. Chan, A.T. Lanas, A. Universidad de Zaragoza (orcid)0000-0001-5932-2889 Rocca, B. Rothwell, P. Patrignani, P. Langley, R. Vilahur, G. Cosentino, F. 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 14, 998 (2020), [24 pp] ecancermedicalscience 1754-6605 633305 http://zaguan.unizar.es/record/95957/files/texto_completo.pdf Versión publicada 441409 http://zaguan.unizar.es/record/95957/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:95957 articulos driver 2023-09-13-10:48:16 ARTICLE